| 000 | 03003 a2200817 4500 | ||
|---|---|---|---|
| 005 | 20250516095414.0 | ||
| 264 | 0 | _c20130117 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1521-009X | ||
| 024 | 7 |
_a10.1124/dmd.112.046052 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSalphati, Laurent | |
| 245 | 0 | 0 |
_aPreclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. _h[electronic resource] |
| 260 |
_bDrug metabolism and disposition: the biological fate of chemicals _cSep 2012 |
||
| 300 |
_a1785-96 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B _xdeficiency |
| 650 | 0 | 4 | _aATP Binding Cassette Transporter, Subfamily G, Member 2 |
| 650 | 0 | 4 |
_aATP-Binding Cassette Transporters _xdeficiency |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aBridged Bicyclo Compounds, Heterocyclic _xadministration & dosage |
| 650 | 0 | 4 | _aCell Membrane Permeability |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aDrug Dosage Calculations |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHepatocytes _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aIntestinal Absorption |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 | _aMCF-7 Cells |
| 650 | 0 | 4 | _aMacaca fascicularis |
| 650 | 0 | 4 | _aMadin Darby Canine Kidney Cells |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Knockout |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinase _xmetabolism |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrimidines _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xgenetics |
| 650 | 0 | 4 | _aSpecies Specificity |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTissue Distribution |
| 650 | 0 | 4 | _aTransfection |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 650 | 0 | 4 | _aATP-Binding Cassette Sub-Family B Member 4 |
| 700 | 1 | _aPang, Jodie | |
| 700 | 1 | _aPlise, Emile G | |
| 700 | 1 | _aLee, Leslie B | |
| 700 | 1 | _aOlivero, Alan G | |
| 700 | 1 | _aPrior, Wei Wei | |
| 700 | 1 | _aSampath, Deepak | |
| 700 | 1 | _aWong, Susan | |
| 700 | 1 | _aZhang, Xiaolin | |
| 773 | 0 |
_tDrug metabolism and disposition: the biological fate of chemicals _gvol. 40 _gno. 9 _gp. 1785-96 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1124/dmd.112.046052 _zAvailable from publisher's website |
| 999 |
_c21863165 _d21863165 |
||